Loading...
FVIIa as used pharmacologically is not TF dependent in hemophilia B mice
Activated factor VII is approved for treating hemophilia patients with autoantibodies to their factor IX or FVIII; however, its mechanism of action remains controversial. Some studies suggest that FVIIa requires tissue factor (TF) for function and that the reason for the high dose requirement is tha...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society of Hematology
2014
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3954056/ https://ncbi.nlm.nih.gov/pubmed/24425804 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-08-522987 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|